Summary: Recent research uncovers a sophisticated survival strategy used by some tumors: they recruit the nervous system to suppress the immune response. A landmark study shows that tumors can activate a neural signaling pathway that instructs the brain to release stress hormones such as glucocorticoids. These hormones blunt the activity of T cells that would normally attack the cancer, revealing a liver–brain–adrenal-like axis that helps explain resistance to certain immunotherapies and opens a new frontier in neuro-immunology for cancer treatment.
The study demonstrates how cancers can manipulate body-to-brain communication to create an immune-suppressive environment. By signaling through peripheral nerves, tumors trigger centrally mediated hormonal and sympathetic responses that effectively raise a molecular “brake” on anti-tumor immunity. Understanding this circuit suggests concrete strategies to sensitize tumors to immunotherapy by interrupting neural or hormonal signals.
Key Facts
- Neural hijacking: Tumors send information along sensory vagus nerve fibers to brainstem centers such as the nucleus tractus solitarius.
- Immune suppression: The brain responds by recruiting the adrenal/sympathetic response to release glucocorticoids and adrenergic signals that suppress immune function.
- Brake on T cells: Hormonal and sympathetic signaling prevents T cells from penetrating and killing tumor cells, allowing cancer to progress.
- Systemic reach: This tumor-driven pathway can dampen immunity beyond the tumor site, producing body-wide effects.
- Therapeutic implication: Blocking specific neural or hormonal nodes in this circuit restores anti-tumor immunity in models and can improve the efficacy of existing immunotherapies.
Source: Yale
A new Nature study maps how tumors communicate with the brain to sabotage the immune system.
Researchers observed that many solid tumors become innervated—invaded by nerve fibers from the peripheral nervous system. Instead of triggering a protective response, those nerves can be co-opted by the tumor to send misleading signals to the brain. The brain then mounts a stress-like, sympathetic and endocrine response that suppresses local anti-tumor immunity and promotes cancer growth.
“Tumors are strategically resourceful,” says Chuyue Yu, a PhD student at Yale School of Medicine and a lead author on the paper. “They tap into normal body circuits to create conditions that favor their own survival.”
Rui Chang, PhD, associate professor of neuroscience and of cellular and molecular physiology at Yale School of Medicine, initially expected that tumor innervation would alert the brain to danger. Instead, the team found that disrupting sensory neurons within tumors caused the cancers to shrink—prompting an investigation into how nerve activity shaped the immune microenvironment.
Using genetically engineered mouse models of lung adenocarcinoma, the researchers selectively manipulated neuron subtypes to test effects on tumor progression. They combined neural tracing and tissue imaging with single-cell sequencing to map which neurons innervate tumors and how those neurons communicate with brain circuits. Collaborative immunology studies profiled the immune cells in the tumor microenvironment and how they responded to neural signals.
Tumor–brain crosstalk blocks immune activity
These experiments revealed a clear pathway: tumor-activated vagal sensory neurons convey signals to the brainstem, which then ramps up sympathetic outflow to the tumor site. Sympathetic neurotransmitters such as norepinephrine act on local immune cells—particularly macrophages—reprogramming them to suppress T cell function. The overall effect is an immune-suppressive microenvironment that permits unhindered tumor growth.
Specifically, norepinephrine-stimulated macrophages adopt phenotypes that block cytotoxic T cells from infiltrating the tumor. In effect, the tumor creates and sustains its own protective niche by manipulating interoceptive sensory nerves and downstream sympathetic–endocrine responses.
“This tumor-to-brain feedback loop helps the cancer evade immune attack,” Chang explains. “If we can interrupt that loop—either at the level of sensory input, sympathetic output or the hormonal signals—there is potential to restore anti-tumor immunity and enhance immunotherapy outcomes.”
The investigators emphasize that tumors vary widely in how they interact with nerves. Some cancers show dense innervation while others lack it, which may influence how aggressively they behave and how they respond to neural interventions. Future work will explore organ-specific tumor–brain circuits and whether neuromodulatory therapies can be tailored to different cancer types.
Funding: This research was supported by the National Institutes of Health (awards R01CA276664 and R01AT012041) and Yale University. Additional funding came from the Damon Runyon Cancer Research Foundation, the Alexander and Margaret Stewart Trust, the Allen Discovery Center, and the Division of Intramural Research. The content is the responsibility of the authors.
Key Questions Answered:
A: Not directly. The study indicates that the tumor itself acts as a stressor by triggering neural signals that look like a stress response. While chronic stress can affect immunity, here the tumor intentionally elicits a brain-mediated response that neutralizes immune cells trying to kill it.
A: Tumors engage vagal sensory neurons—an internal signaling highway—to send molecular cues to brainstem centers. Those cues are interpreted as interoceptive signals that then trigger sympathetic and hormonal outputs.
A: In preclinical models, interrupting the sensory-to-sympathetic pathway—genetically, pharmacologically, or chemogenetically—reduced tumor growth and improved immune control. Translating these strategies into clinical neuromodulation or drug approaches could augment immunotherapy in patients.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full by the editorial team.
- Additional context was provided by staff contributors.
About this brain cancer research news
Author: Isabella Backman
Source: Yale
Contact: Isabella Backman – Yale
Image: Image credited to Neuroscience News
Original Research: Open access. “Tumour–brain crosstalk restrains cancer immunity via a sensory–sympathetic axis” by Haohan K. Wei, Chuyue D. Yu, Bo Hu, Xing Zeng, Hiroshi Ichise, Liang Li, Yu Wang, Ruiqi L. Wang, Ronald N. Germain, Rui B. Chang & Chengcheng Jin. DOI: 10.1038/s41586-025-10028-8
Abstract
Tumour–brain crosstalk restrains cancer immunity via a sensory–sympathetic axis
Body–brain communication is an important regulator of tissue homeostasis, and solid tumors are often innervated by branches of the peripheral nervous system. Increased tumor innervation is associated with worse cancer outcomes, but the mechanisms by which the brain senses peripheral tumors and influences anti-cancer immunity remained unclear.
The study identifies a tumor–brain axis that promotes tumor growth by creating an immune-suppressive microenvironment. Using genetically engineered mouse models, neural tracing, tissue imaging and single-cell transcriptomics, the authors show that lung adenocarcinoma drives innervation and activation of vagal sensory neurons, which connect visceral organs to brainstem centers. Npy2r-expressing vagal sensory fibers transmit tumor-derived signals to the brainstem, increasing sympathetic efferent activity in the tumor microenvironment. This sympathetic output suppresses anti-tumor immunity through β2-adrenergic signaling in alveolar macrophages. Genetic, pharmacological or chemogenetic disruption of the sensory-to-sympathetic pathway significantly reduced lung tumor growth by enhancing immune responses.
These results reveal a bidirectional tumor–brain communication circuit that regulates anti-cancer immunity and suggest that targeting this pathway could provide new therapeutic strategies for visceral organ cancers.